Yi-Fan Li

Yi-Fan Li

Auto-generated profile, based on publicly available information

Yi-Fan Li

Graduate School of Beijing University of Chinese Medicine, Beijing 100029, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
WQWangjun Qin
Wangjun Qin
YLYifan Li
Yifan Li
BLBotao Liu
Botao Liu
YLYing Liu
Ying Liu
YZYi Zhang
Yi Zhang
BFBifa Fan
Bifa Fan
Purpose: Intrathecal morphine infusion therapy via a percutaneous port (IMITPP) has been used widely for its relatively low initial cost. However, there is scarce knowledge about IMITPP. In this study, we sought to evaluate efficacy, complications, and the interval required to achieve the cost equivalence of IMITPP in patients with refractory cancer pain in China. Patients and Methods: A retrospective chart review was conducted on cancer patients who had received IMITPP at our hospital between April 2017 and April 2019. Data from the numeric pain rating scale and Karnofsky performance scores, and complications and costs related to IMITPP were collected from medical records. Daily analgesic costs before and after IMITPP were calculated based on the doses of opioids on admission and at discharge, respectively. The doses of systemic opioids before IMITPP were stratified into very high doses [VHD, oral morphine equivalent dose (OMED) > 599 mg/day], high doses (HD, 300 mg/day ≤ OMED ≤ 599 mg/day), and regular doses (RD, OMED < 300 mg/day). Results: Intrathecal morphine infusion therapy via a percutaneous port provided significant pain relief, but impaired activities of daily living in patients with refractory cancer pain. The commonly reported complications included nausea/vomiting and urinary retention, most of which were managed with symptomatic therapies. The median interval required to achieve cost equivalence was 11.44 months. The median intervals of VHD group and HD group were significantly shorter than that of RD group. Conclusion: Intrathecal morphine infusion therapy via a percutaneous port provided effective cancer pain management without causing serious complications. Patients with higher doses of systemic opioids would economically benefit from IMITPP in a shorter time.

1 May 2019 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
YLYi-Fan Li
Yi-Fan Li
PMPeng Mao
Peng Mao
QZQian Zhu
Qian Zhu
BLBo-Tao Liu
Bo-Tao Liu
BFBi-Fa Fan
Bi-Fa Fan
Objective: To report a successful attempt of peripheral nerve field stimulation (PNFS) in preauricular area to treat refractory chronic migraine (CM). This article focuses on novel utilization of PNFS and discusses its existing issues. Case report: A 35-year-old woman diagnosed with CM complained about a 2-year history of severe pain at the occipitocervical and left auriculotemporal area, sometimes bilaterally, which did not benefit from conventional medical therapy. After failed attempts of occipital nerve stimulation and PNFS at the retroauricular area, we used exploratory PNFS at the preauricular area, which to our knowledge is the first reported case in literature, to such an area in refractory CM. The patient experienced satisfactory pain relief and obvious improvement in quality of life. And the amelioration on the severity of pain was validated by reduced scores (from 9 to 2) on the numerical rating scale. The clinical effects continued in the next 2-year follow-up after the implantation, without adverse events. Conclusion: PNFS is a promising and safe neuromodulation therapy for refractory CM. Facial areas like preauricular region are applicable for lead implantation. Nevertheless, the underlying mechanisms are still unverified, and there is still a lack of standardized operation guides of PNFS. Large-scale randomized clinical trials should be conducted to further validate these findings.

22 December 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YLYi-Fan Li
Yi-Fan Li
HHHui-Min Hu
Hui-Min Hu
BWBo-Ning Wang
Bo-Ning Wang
YZYi Zhang
Yi Zhang
XLXing Liu
Xing Liu
BFBifa Fan
Bifa Fan
Objective. To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. Method. This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). Results. A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group ( ). No severe adverse events were observed in this trial. Conclusion. Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile.